Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma

Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma

An exposure–response (E–R) safety analysis was conducted across adult and pediatric (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CPT: Pharmacometrics & Systems Pharmacology 2024-01, Vol.13 (1), p.168-179
Hauptverfasser: Du, Shengnan, Zhao, Yue, Hu, Zheyi, Liu, Sihang, Roy, Amit, Shen, Jun, Zhu, Li, Hamuro, Lora
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Adults
Analysis
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Child
Drug dosages
Female
Humans
Ipilimumab
Ipilimumab - adverse effects
Male
Medical research
Medicine, Experimental
Melanoma
Melanoma - drug therapy
Melanoma - pathology
Monoclonal antibodies
Neoplasm Staging
Nivolumab
Oncology
Optimization
Patients
Pediatrics
Safety and security measures
Teenagers
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An exposure–response (E–R) safety analysis was conducted across adult and pediatric (
ISSN:2163-8306
2163-8306
DOI:10.1002/psp4.13070